Document is current
Any future updates will be listed below
-
Authors
Verma, Aditya https://orcid.org/0000-0003-3778-8834
Nittala, Muneeswar G.
Dara, Roxan Mansoori
Facktor, Marius
Ramachandra, Chaithanya A.
Bhaskaranand, Malavika
Bhat, Sandeep
Solanki, Kaushal
Jayadev, Chaitra https://orcid.org/0000-0001-8392-7159
Velaga, Swetha B. https://orcid.org/0000-0002-4637-6914
Robertson, Gavin
Yates, Bradley
Raman, Rajiv https://orcid.org/0000-0001-5842-0233
Sadda, SriniVas R. https://orcid.org/0000-0002-4939-3306
-
Funding
Funding for this research was provided by:
Employed at Eyenuk
Employed at Optos Plc
Employed at Optos PLc
- License Information
-
More Information
Article History
Received: 19 April 2025
Revised: 3 December 2025
Accepted: 18 December 2025
First Online: 16 January 2026
Competing interests
: Rajiv Raman is a member of the Eye editorial board. No conflicting relationships exist for any author. AV, MGN, RMD: None; MF, CAR, MB, SB, KS: employee at Eyenuk, Inc.; CJ, SBV, RR: None; GR, BY: Employed at Optos Plc; SRS: Consultant (C): 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., iCare, GENENTECH, Jannsen, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion/Thrombogenics, Eyepoint, ONL Tx, Ocular Tx, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. Recipient (R): Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Roche; Topcon Medical Systems Inc. Financial Support (F): Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue.
